Last reviewed · How we verify
CHOP combined with CMAB304
CHOP chemotherapy combined with CMAB304 (a monoclonal antibody) targets cancer cells through cytotoxic chemotherapy while enhancing immune response through antibody-mediated mechanisms.
CHOP chemotherapy combined with CMAB304 (a monoclonal antibody) targets cancer cells through cytotoxic chemotherapy while enhancing immune response through antibody-mediated mechanisms. Used for Lymphoma or hematologic malignancy (specific indication not publicly confirmed).
At a glance
| Generic name | CHOP combined with CMAB304 |
|---|---|
| Also known as | cyclophosphamide, doxorubicin, vincristine, prednisone |
| Sponsor | Shanghai CP Guojian Pharmaceutical Co., Ltd. |
| Drug class | Combination therapy: chemotherapy + monoclonal antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CHOP is a standard combination chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) that kills rapidly dividing cancer cells. CMAB304 is a monoclonal antibody that likely enhances anti-tumor immunity or blocks a specific tumor-associated target. The combination aims to improve efficacy over chemotherapy alone by leveraging both cytotoxic and immunological mechanisms.
Approved indications
- Lymphoma or hematologic malignancy (specific indication not publicly confirmed)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Alopecia
- Infection
- Cardiotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHOP combined with CMAB304 CI brief — competitive landscape report
- CHOP combined with CMAB304 updates RSS · CI watch RSS
- Shanghai CP Guojian Pharmaceutical Co., Ltd. portfolio CI